2015 Press Releases

Receive E-mail AlertsEmail Alerts
Sign up to receive e-mail alerts whenever MannKind has a news release. Just enter your e-mail address and click submit.
2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
07/29/15MannKind Announces Stock and Note Exchange Agreements With Holders of Outstanding 5.75% Senior Convertible Notes
VALENCIA, Calif., July 29, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (the "Company" or "MannKind") (Nasdaq:MNKD) today announced that it has entered into separate, privately-negotiated exchange agreements with select holders of its existing 5.75% Senior Convertible Notes due 2015 (the "2015 notes") to exchange up to an aggregate principal amount of $84.6 million of the 2015 notes. Pursuant to the exchange agreements with certain holders (the "Note Exchange Agreements"), the Company has agree... 
Printer Friendly Version
06/09/15Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala
Mann, Early Developer of Pacemaker, Artificial Pancreas and Inhaled Insulin is Honored BOSTON, June 9, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a leading biopharmaceutical company focused on patient experience, acknowledged today that Executive Chairman Alfred Mann was honored last night at a gala for his extensive work in the progression and advancement of diabetes technologies and advocacy. Held in conjunction with the 75th annual American Diabetes Association Scientif... 
Printer Friendly Version
05/27/15MannKind to Present at Upcoming Conferences
VALENCIA, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences.  Jefferies 2015 Global Healthcare Conference on Wednesday, June 3, 2015 at 2:00 pm (ET) in New York, New York. Goldman Sachs 36th Annual Global Healthcare Conference on Wednesday, June 10, 2015 at 8:40 am (PT) at the Terranea Resort in Rancho Palos Verdes, ... 
Printer Friendly Version
05/21/15James S. Shannon Rejoins MannKind's Board of Directors
VALENCIA, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that James S. Shannon, MD, MRCP (UK) has been elected to the company's Board of Directors after previously serving as a director from February 2010 until April 2012. The addition of Dr. Shannon brings the total number of MannKind Board members to eight. From May 2012 until his retirement in April 2015, Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. He formerly held the positio... 
Printer Friendly Version
05/07/15MannKind Corporation Reports 2015 First Quarter Financial Results
- Conference Call at 9:00 AM ET on May 8, 2015 - VALENCIA, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, total operating expenses were $21.7 million, a decline of 47.5% compared to the similar quarter in 2014. Research and development expenses were $9.4 million, a decline of 64.2% compared to the first quarter of 2014, reflecting the commercialization of A... 
Printer Friendly Version
05/06/15MannKind to Present at Bank of America Merrill Lynch 2015 Healthcare Conference
VALENCIA, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2015 Healthcare Conference on Wednesday, May 13, 2015 at 12:00 pm Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada. Interested parties can access a link to the live webcast of the presentations from the News & Events section ... 
Printer Friendly Version
04/30/15MannKind Corporation to Hold 2015 First Quarter Financial Results Conference Call on May 8, 2015
VALENCIA, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2015 first quarter financial results on Thursday, May 7, 2015 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 9:00 AM (Eastern Time) on May 8, 2015. Presenting from the Company will be its Chief Executive Officer, Hakan Edstrom and Chief Financial Officer, Matthew Pfeffer. To participate in the live call b... 
Printer Friendly Version
04/27/15MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval
VALENCIA, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it will begin to manufacture a 12 unit cartridge strength of AFREZZA (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes. The 12 unit cartridge was approved by the U.S. Food and Drug Administration on April 17, 2015 and is expected to be launched by Sanofi in the second half of 2015. The new dosage strength complements the existing 4 unit and ... 
Printer Friendly Version
02/24/15MannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results
- Conference Call to Begin Today at 5:00 PM ET - VALENCIA, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2014. For the fourth quarter, our operating expenses declined 35% compared to the similar quarter in 2013. Research and development costs were significantly lower, mainly due to a reduction in non-cash compensation expenses and much lower clinical trial expenses followi... 
Printer Friendly Version
02/18/15MannKind Corporation to Present at the RBC Capital Markets Global Healthcare Conference
VALENCIA, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the 2015 RBC Capital Markets Global Healthcare Conference on Wednesday, February 25, 2015 at 9:00 AM (ET) at the New York Palace in New York City.    Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company'... 
Printer Friendly Version
02/17/15MannKind Corporation to Hold 2014 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2015
VALENCIA, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 fourth quarter and full year financial results on Tuesday, February 24, 2015 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on February 24, 2015. Presenting from the Company will be its Chief Executive Officer, Hakan Edstrom and Chief Financial Officer, Matthew Pfeffe... 
Printer Friendly Version
02/03/15Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
PARIS and VALENCIA, Calif., Feb. 3, 2015 /PRNewswire/ -- Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes. Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7412351-sanofi-ma... 
Printer Friendly Version
01/12/15MannKind CEO Alfred Mann to Transition to Executive Chairman; COO and President Hakan Edstrom Appointed to CEO
Alfred Mann to Remain Focused on Development and Financing of Future Products of MannKind VALENCIA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a biopharmaceutical-based technology company, today announced that Alfred Mann, the company's founder, retired from his role as Chief Executive Officer effective January 9, 2015 and will transition to Executive Chairman. Mr. Mann intends to remain engaged with the company in business matters, including those relating to... 
Printer Friendly Version
01/08/15MannKind Earns $50 Million in Milestone Payments From Sanofi
VALENCIA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it has earned a total of $50 million in milestone payments in connection with the satisfaction of manufacturing milestones specified in its collaboration and licensing agreement with Sanofi. Pursuant to the agreement, MannKind previously received a $150 million upfront payment and is eligible to earn up to $725 million in further development, regulatory and sales milestones, and is also eli... 
Printer Friendly Version
01/07/15MannKind Corporation to Present at the J.P. Morgan 2015 Healthcare Conference
VALENCIA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the 33RD Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 1:30 PM (PST) at Westin St. Francis Hotel in San Francisco, California. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Com... 
Printer Friendly Version


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet